Allogene Therapeutics
Jin Yang is a Senior Scientist at Allogene Therapeutics, with experience in the biotechnology sector since November 2019, having previously served as a Scientist at Refuge Biotechnologies. Jin's academic background includes a Doctor of Philosophy in biophysics from the University of Chinese Academy of Sciences and a Bachelor of Science in biology from Wuhan University. Prior research experience includes positions as a research specialist at both UCSF Medical Center and Duke University, as well as a Postdoctoral Research Fellow at HHMI from October 2004 to September 2009.
This person is not in the org chart
Allogene Therapeutics
1 followers
Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first generation autologous CAR T therapies to deliver breakthrough clinical benefits but eliminate the need to create a personalized therapy for each patient. Instead, we start with T cells from healthy donors, which is intended to allow for creation of inventory for “off-the-shelf” use in patients faster, more reliably, and at greater scale.